

**Supplement Table 3: Patient Treatment prior to and followin**

Study ID	Immediate Pre-PDO Treatment	Pre-PDO Treatment start date (days from diagnosis)	Pre-PDO Treatment end date (days from diagnosis)
3	FOLFIRINOX	450	657
6	gemcitabine/nab-paclitaxel (added paracalc)	288	394
10			
19			
34			
38			
52	FOLFIRINOX	427	441
75			
76	5FU Nal-irinotecan Pembrolizumab	341	586

numbers are days from diagnosis

## g tissue biopsy for organoids and target lesion sizes

Baseline Scan. Target lesion(s) long axis (mm)	F/u scan after pre-PDO Tx. Target lesion(s) long axis (mm)
pancreas 29	pancreas 26
pancreas 13, liver 12	pancreas 17, liver 14
RECIST baseline by clinical trial	
pancreas 22, liver1 32, liver2 20	
pancreas 25, Liver 20	
pancreas 72, Liver1 34, Liver2 31, Liver3 21, Right hilum 23	
pancreas 30	pancreas 23
pancreas 35	
pancreas 23	pancreas 16

Green = PR (partial response by RECIST 1.1)

Yellow = SD (stable disease by RECIST 1.1)

Red = PD (progressive disease by RECIST 1.1)

Tissue obtained for PDO (days from diagnosis)	Initial Drug Testing Completed (days from diagnosis)	Additional Drug Testing Completed (days from diagnosis)	Post-PDO Tx1
475	571	773	FOLFIRINOX
372	503	709	
0	91	350	gemcitabine/nab-paclitaxel
14	120	314	gemcitabine/nab-paclitaxel
43	136	411	FOLFOX
779	867	990	gemcitabine/nab-paclitaxel
458	493	493	FOLFOX
336	436	462	gemcitabine/nab-paclitaxel
755	840	840	5Fu nalirinotecan pembrolizumab

<b>F/u scan (after post-PDO tx). Target lesion(s) long axis (mm)</b>	<b>Post-PDO Tx2</b>	<b>F/u scan 3. Target lesion(s) long axis (mm)</b>
pancreas 23	trametinib/lapatinib	pancreas 20
f/u scans with RECIST q2 months per clin	5FU Nal-irinotecan	
pancreas 17, liver1 22, liver2 20		
pancreas 28, liver 33		
pancreas 59, Liver1 30, Liver2 28, Liver3 30	FOLFOX	
pancreas 25 PD non-target + ascites	FOLFIRI	pancreas 24
pancreas 52		
)		

**F/u scan 4.**  
**Target**  
**lesion(s) long**  
**axis (mm)**

pancreas 16

---

---

---

---

---

---

---

---